QH101 / Beijing Qinghui Liannuo Biotechnology - LARVOL DELTA

Rare Tumor Focused Platform Study of Innovative Therapies and Technologies (PLATFORM2) (clinicaltrials.gov) - P1/2 | N=600 | Not yet recruiting | Sponsor: Cancer Institute and Hospital, Chinese Academy of Medical Sciences

IO biomarker • New P1/2 trial • Oncology • Solid Tumor

QH101 Cell Therapy Relapsed/Refractory(R/R) Acute Myeloid Leukemia(AML) and Myelodysplastic Syndromes(MDS) (clinicaltrials.gov) - P1 | N=9 | Not yet recruiting | Sponsor: Anhui Provincial Hospital

New P1 trial • Acute Myelogenous Leukemia • Hematological Malignancies • Leukemia • Myelodysplastic Syndrome • Oncology